GOSS 10-Q: SEC filing
Gossamer Bio
Filed with the SEC on · accession 0001728117-26-000114
GOSS filed a 10-Q (quarterly report) with the SEC on Nov 10, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved +6.0% by the first close after the filing.
Summary of the filing
Gossamer Bio filed its Q3 2026 Form 10-Q, reporting quarterly financial results including revenue from its collaboration with Chiesi and ongoing expenses related to its drug development programs.
Key details
How GOSS stock reacted
Close before
$10.64
Nov 9, 2026
First close after
+5.97%
$11.28
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for GOSS, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for GOSS?
Click hereFrequently asked questions
What did GOSS file with the SEC on Nov 10, 2026?
GOSS filed a 10-Q (SEC filing). Gossamer Bio filed its Q3 2026 Form 10-Q, reporting quarterly financial results including revenue from its collaboration with Chiesi and ongoing expenses related to its drug development programs.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did GOSS stock react to this filing?
GOSS closed at $10.64 before the filing and $11.28 on Nov 10, 2026 (+5.97%).
Other GOSS SEC filings
- 8-K · SEC filingNov 10, 2026
- SCHEDULE 13G/A · SEC filingNov 6, 2026
- SCHEDULE 13G · SEC filingNov 6, 2026
- SCHEDULE 13D/A · Insider sale plannedOct 29, 2026
- 8-K · SEC filingOct 28, 2026
- SCHEDULE 13D/A · Insider sale plannedOct 8, 2026
- 8-K · Delisting noticeSep 28, 2026
- SCHEDULE 13D/A · Insider sale plannedSep 28, 2026
- 8-K · Fda approvalSep 23, 2026
- 8-K · Board changeSep 16, 2026
Get alerts when GOSS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days